Antibodies as predictors of autoimmune diseases and cancer

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 6, 2008, Pages 593-605

  Vodjani, Aristo ^a  

^a Immunosciences Laboratories Inc   (United States)

Author keywords

Autoantibodies; Autoimmune diseases; ELISA; Environmental factors

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; CANCER ANTIBODY; CYTOKINE; TISSUE ANTIGEN; TUMOR ANTIGEN;

ADRENAL DISEASE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; CANCER GROWTH; CARCINOGENESIS; COST OF ILLNESS; CROSS REACTION; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL DISEASE; HEART DISEASE; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EXAMINATION; MICROARRAY ANALYSIS; NEUROIMMUNOLOGY; NEUROLOGIC DISEASE; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PREDICTION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROLOGY; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; TISSUE SPECIFICITY; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 77953413838     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2.6.593     Document Type: Review

References (156)

1. Notkins AL. New predictors of disease. Sci Am 2007;296:72-9
2. Levine BB, Zolov DM. Prediction of penicillin allergy by immunologic tests. J Allergy 1969;43:231-44
3. Zeiss CR, Wolkonsky P, Pruzansky JJ, Patterson R. Clinical and immunologic evaluation of trimellitic anhydride workers in multiple industrial setting. J Allergy Clin Immunol 1982;70:15
4. Sequin P, Allard A, Cartier A, Malo JL. Prevalence of occupational asthma in spray painters exposed to several types of isocyanates. J Occup Med 1987;29:340
5. Roby RR, Richardson RH, Vojdani A. Hormone allergy. Am J Reprod Immunol 2006;55:307-13
6. Lee S, Goswami S, Gurdo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007;13:567-9
7. Wildner G, Diedrichs-Moehring M. Multiple autoantigen mimotopes of infectious agents induce autoimmune arthritis and uveitis in Lewis rats. Clin Diag Lab Immunol 2005;12:677-9
8. Vojdani A, Bazargan M, Vojdani E, et al. Heat shock protein and gliadin peptide promote development of peptidase antibodies in children with autism and patients with autoimmune disease. Clin Diagn Lab Immunol 2004;11(3):515-24
9. Vojdani A, Pangborn JB, Vojdani E, Cooper EL. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int J Immunopathol Pharmacol 2003;16(3):189-99
10. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004;84:282-97
11. Fasano A, Shea-Donohue T. Mechanisms of disease the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005;2:416-22
12. Ware JA, Graf MLM, Martin BM, et al. Immunochemical detection and identification of protein adducts of diclofenac in small intestine of rats: possible role in allergic reactions. Chem Res Toxicol 1998;19:133-41
13. Griem P, Wulferink M, Sachs B, et al. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998;19:133-41
14. Takeuchi K, Turley SJ, Tan EM, Pollard KM. Analysis of the autoantibody response to fibrillarin in human disease and murine model of autoimmunity. J Immunol 1995;154:961-71
15. Leung PSC, Park O, Tsuneyama K, et al. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J Immunol 2007;179:2651-7
16. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001;108:1417-22
17. Shepshelovich D, Shoenfeld Y. Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. Lupus 2006;15:183-90
18. Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 2007;56:1736-44
19. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232-6
20. Seibold F. ASCA genetic marker, predictor of disease, or marker of a response to an environmental antigen? Gut 2005;54:1212-3
21. Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann NY Acad Sci 2006;1069:322-45
22. Pamer EG. Immune responses to commensal and environmental microbes. Nat Immunol 2007;8:1173-8
23. James D, Asherson G, Chanarin I, et al. Cell-mediated immunity to intrinsic factor in autoimmune disorders. BMJ 1974;4:494-6
24. Varis K, Samloff IM, Ihamaki T, Siurala M. An appraisal of tests for severe atrophic gastritis in relative of patients with pernicious anaemia. Dig Dis Sci 1979;24:187-91
25. Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin: a clue to the pathogenic mechanism for ulcerative colitis. J Immunol 1993;150:2487
26. Nakamura H, Hinoda Y, Nakagawa N, et al. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 1998;33:354-61
27. Vader W, Kooy Y, van Veelen P, et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002;122:1729-37
28. Marti T, Molberg O, Li Q, et al. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther 2005;312:19-26
29. McMillan SA, Haughton DJ, Biggart JD, et al. Predictive value for celiac disease of antibodies to gliadin, endomysium, and jejunum in patients attending for jejunal biopsy. BMJ 1991;303:1163-5
30. Seissler J, Boms S, Wohlrab U, et al. Antibodies to human recombinant tissue transglutaminase measured by radioligand assay; evidence for high diagnostic sensitivity for celiac disease. Horm Metab Res 1999;31:375-9
31. Dieterich W, Laag E, Schopper H, et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology 1998;115:1317-21
32. Marks J, Shuster S, Watson AJ. Small bowel changes in dermatitis herpetiformis. Lancet 1966;2:1280-2
33. Cooke WT, Thomas-Smith W. Neurological disorders associated with adult celiac disease. Brain 1996;89:683-722
34. Stagi S, Giani T, Simonini G, Falcini F. Thyroid function, autoimmune thyroiditis and coeliac disease in juvenile idiopathic arthritis. Rheumatology 2005;44:517-20
35. Molberg O, Sollid LM. A gut feeling for joint inflammation: using celiac disease to understand rheumatoid arthritis. Trends Immunol 2006;27:188-94
36. Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002;105:2611-8
37. Cronin CC, Shanahan F. Insulin-dependent diabetes mellitus and coeliac disease. Lancet 1997;349:1096-7
38. Hadjivassiliou M, Williamson CA, Woodroofe N. The immunology of gluten sensitivity beyond the gut. Trends Immunol 2004;25:578-82
39. Hadjivassiliou M, Williamson C, Gr newald RA, et al. Glutamic acid decarboxylase as a target antigen in gluten sensitivity: the link to neurological manifestations? Proceedings of the 11th International Symposium on Coeliac Disease; Belfast, Ireland; 2004
40. Alaedini A, Okamoto H, Briani C, et al. Immune cross-reactivity in celiac disease: anti-gliadin antibodies bind to neuronal synapsin I. J Immunol 2007;178:6590-5
41. Zanoni G, Navone R, Lunardi C, et al. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 2006;3(9):e358. doi:10.1371/ journal.pmed.0030358
42. Blutt SE, Crawford SE, Warfield KL, et al. The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation. J Virol 2004;78:6974-81
43. Rutgeerts P, Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology 1998;115:1006-22
44. Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med 1989;321:16-24
45. Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 2004;53:1155-60
46. Wayne LG, Hollander D, Anderson B, et al. Immunoglobulin A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. J Clin Microbiol 1992;30:2013-8
47. Rapoport B, McLachlan SM. Thyroid autoimmunity. J Clin Invest 2001;108:1253-9
48. Rosenthal MJ, Hunt WC, Garry PJ, Goodwin JS. Thyroid failure in the elderly. Microsomal antibodies as discriminant for therapy. JAMA 1987;258:209-13
49. Vanderpump MP, Turnbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf) 1995;43:55-68
50. Moreno M, Berry MJ, Horst C, et al. Activation and inactivation of thyroid hormone by type I iodothyronine deiodinase. FEBS Lett 1994;344:143-6
51. Chistiakov DA. Thyroid-stimulating hormone receptor and its role in Graves' disease. Mol Gen Metab 2003;80:377-88
52. Szkudlinski MW, Fremont V, Ronon C, Weintraub BD. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationship. Physiol Rev 2002;82:473-502
53. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33
54. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
55. Mahler M, Stinton LM, Fritzler MJ. Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay. Clin Diagn Lab Immunol 2005;12:107-13
56. Grader-Beck T, Casciola-Rosen L, Lang TJ, et al. Apoptotic splenocytes drive the autoimmune response to poly (ADP-ribose) polymerase 1 in a murine model of lupus. J Immunol 2007;178:95-102
57. Deocharan B, Zhou Z, Antar K, et al. α-actinin immunization elicits anti-chromatin autoimmunity in nonautoimmune mice. J Immunol 2007;179:1313-21
58. Girbal-Neuhauser E, Durieux J-J, Arnaud M, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deamination of arginine residues. J Immunol 1999;162:585-94
59. van Gaalen F, Ioan-Facsinay A, Huizinga TWJ, Toes REM. The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. J Immunol 2006;175:5575-80
60. Cook AD, Gray R, Ramshaw J, et al. Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis. Arthritis Res Ther 2004;6:R477-83
61. Carty SM, Snowden S, Silman AJ. Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? Ann Rheum Dis 2004;63(Suppl 2):ii46-9
62. Wildner G, Diedrichs-Mohring M, Thurau SR. Induction of arthritis and uveitis in Lewis rats by antigenic mimicry of peptides from HLA-B27 and cytokeratin. Eur J Immunol 2002;32:299-306
63. Tsuruha J, Masuko-Hongo K, Kato T, et al. Autoimmunity against YKL-39, a human cartilage derived protein, in patients with osteoarthritis. J Rheumatol 2002;29:1459-66
64. Xiang Y, Sekine T, Nakamura H, et al. Proteomic surveillance of autoimmunity in osteoarthritis: identification of triose phophate isomerase as an autoantigen in patients with osteoarthritis. Arthritis Rheum 2004;50:1511-21
65. Xiang Y, Sekine T, Nakamura H, et al. Fibulin-4 is a target of autoimmunity predominantly in patients with osteoarthritis. J Immunol 2006;176:3196-204
66. Reuter R, Tessars G, Vohr HW, et al. Mercuric chloride induces autoantibodies against U3 small nuclear ribonucleoprotein in susceptible mice. Proc Natl Acad Sci USA 1989;86:237-41
67. Hultman P, Bell LJ, Enestrom S, Pollard KM. Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in inbred, congenic and intra-H-2 recombinant strains. Clin Immunol Immunopathol 1992;65:98-109
68. Kono DH, Balomenos D, Pearson DL, et al. The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-γ and not Th1/Th2 imbalance. J Immunol 1998;161:234-40
69. Betterle C, Volpato M, Rees Smith B, et al. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease. J Clin Endocrinol Metab, 1997;82:939-42
70. Arends J, Wu J, Borillo J, et al. T cell epitope mimicry in antiglomerular basement membrane disease. J Immunol 2006;176:1252-8
71. Leslie RDG, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in type I (insulin-dependent) diabetes. Diabetologia 1999;42:3-14
72. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350:1288-93
73. Bonifacio E, Lampasona V, Genovese S, et al. Identification of protein tyrosine phosphatase-like IA2 (isle T cell antigen 512) as the insulin-dependent diabetes-related 37/40k autoantigen and a target of isleT cell antibodies. J Immunol 1995;155:5419-26
74. Yu L, Robles DT, Adiru N, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 2000;97:1701-6
75. Clements GB, Galbraith DN, Taylor KW. Coxsackie B virus infection and onset of childhood diabetes. Lancet 1995;346:221-3
76. Virtanen SM, Laara E, Hypponen E, et al. Cow's milk consumption, HLA-DQB1 genotype, and type 1 diabetes. A nested case-control study of siblings of children with diabetes. Diabetes 2000;49:912-7
77. Rose NR, Neumann DA, Herkowitz A. Autoimmune myocarditis: concepts and questions. Immunol Today 1991;12:253-6
78. Cook PJ, Honeybourne D, Lip GY, et al. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischaemia: The West Birmingham Stroke Project. Stroke 1991;29:401-10
79. Gaunt CJ. Epitopes shared between coxsackievirus B3 (CVB3) and normal heart tissue contribute to CVB3-induced murine myocarditis. Clin Immunol Immunopathol 1993;68:129-34
80. Shaw PX, Goodyear CS, Chang M, et al. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cell. J Immunol 2003;170:6151-7
81. Chen XX, Gu YY, Li SJ, et al. Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice. J Immunol 2007;178:5351-6
82. Danese S, Dejana E, Fiocchi C. Immune regulation by microvascular endothelial cells: directing innate and adoptive immunity, coagulation and inflammation. J Immunol 2007;178:6017-22
83. Kornbegr A, Renaudineau Y, Blank M, et al. Anti-beta-2-glycoprotein-1 antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. IMAJ 2000;2(Suppl):27-31
84. Toubi E, Shoenfeld Y. Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality? Lupus 2005;14:665-9
85. Vojdani A, Vojdani E, Cooper EL. Antibodies to myelin basic protein, myelin oligodendrocytes peptides, α-B-crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis. J Intern Med 2003;254:363-74
86. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-5
87. Holz A, Bielekova B, Martin R, Oldstone MBA. Myelin-associated oligodendrocyte basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis. J Immunol 2000;164:1103-9
88. Berger T, Rubner P, Schnautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after first demyelinating event. N Engl J Med 2003;349:139-45
89. Mantegazza R, Cristaldini P, Bernasconi P, et al. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. Int Immunol 2004;16:559-65
90. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:2280-5
91. Gaertner S, de Graaf KL, Grene B, Weissert R. Antibodies against glysocylated native MOG are elevated in patients with multiple sclerosis. Neurology 2004;63:2381-3
92. O'Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005;175:1974-82
93. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007;356:371-8
94. Esposito M, Venkatesh V, Otvos L, et al. Human transaldolase and cross-reactive viral epitopes identified by autoantibodies of multiple sclerosis patients. J Immunol 1999;163:4027-32
95. Grogan JL, Kramer A, Nogai A, et al. Cross-reactivity of myelin basic protein-specific T-cells with multiple microbial peptides: experimental autoimmune encephalomyelitis induction in TCR transgenic mice. J Immunol 1999;163:3764-70
96. Tsunoda I, Libbey JE, Fujinami RS. Sequential polymicrobial infections lead to CNS inflammatory disease: possible involvement of bystander activation in heterologous immunity. J Neuroimmunol 2007;188:22-33
97. Wirguin I, Suturkova-Milosevic LJ, Della-Latta P, et al. Monoclonal IgM antibodies to GM1 and asialo-GM1 in chronic neuropathies cross-react with Campylobacter jejuni lipopolysaccharides. Ann Neurol 1994;35:698
98. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Camplyobacter enteritis. Neurology 1990;40:1900-2
99. Nobile-Orazio E, Carpo M, Meucci N, et al. Guillain Barre syndrome associated with high titers of anti-GM1 antibodies. J Neurol Sci 1992;109:200
100. Peggy C, Godschalk R, Kujif ML, et al. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes. Infect Immun 2007;75:1245-54
101. Ang CW, Jacobs BC, Laman JD. The Guillain-Barre syndrome a true case of molecular mimicry. Trends Immunol 2004;25:61-6
102. Ang CW, Laman JD, Willison HJ, et al. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barre and Miller Fisher patients. Infect Immunol 2002;70:1202-8
103. Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994;265:648-51
104. Rogers SW, Twyman RE, Gahring LC. The role of autoimmunity to glutamate receptors in neurological disease. Mol Med Today 1996;2:76-81
105. Gahring LC, Carlson NG, Meyer EL, Rogers SW. Cutting edge: granzyme B proteolysis of a neuronal glutamate receptor generates an autoantigen and is modulated by glycosylation. J Immunol 2001;166:1433-8
106. Rakhit R, Robertson J, Velde CV, et al. An immunological epitope selective for pathological monomer - misfolded SOD1 in ALS. Nat Med 2007;13:754-9
107. Galvin JE, Hemric ME, Ward K, Cunningham MW. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest 2000;106:217-24
108. Kirvan CA, Swedo SE, Heurser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003;9:914-20
109. Mell LK, Davis RL, Owens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. Pediatrics 2005;116:56-60
110. Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin is a neuronal target of autoantibodies in Sydenham's chorea. J Immunol 2007;178:7412-21
111. Missmer SA, Suarez L, Felkner M, et al. Exposure to fumonisins and the occurrence of neural tube defects along the Texas-Mexico border. Environ Health Perspect 2006;114:237-41
112. Allen SD, Garrett JT, Rawale SV, et al. Peptide vaccines of the HER-2/ neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2002;179:472-82
113. McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 1999;163:3718-26
114. Penna G, Amuchastegui S, Cossetti C, et al. Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. J Immunol 2007;179:1559-67
115. Siegel S, Wagner A, Friedrichs B, et al. Identification of HLA-A*0201-Presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J Immunol 2006;176:6935-44
116. Soussi T. P53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88
117. Nilsson BO, Carlsson L, Larsson A, Ronquist G. Autoantibodies to prostasomes as new markers for prostate cancer. Ups J Med Sci 2001;106:43-9
118. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54
119. Brichory FM, Misek DE, Yin AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001;98:9824-9
120. Soares MM, Mehta V, Fin OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001;166:6555-63
121. Motrich SW, Maccioni M, Ponce AA, et al. Pathogenic consequences in semen quality of an autoimmune response against the prostate gland: from animal models to human disease. J Immunol 2006;177:957-67
122. Toubi E, Shoenfeld Y. Protective autoimmunity in cancer. Oncol Rep 2007;17:245-51
123. Werner JA, Gottschlich S, Folz BJ, et al. p53 serum antibodies as prognostic indicator in head and neck cancer. Cancer Immunol Immunother 1997;44:112-6
124. Sangrajrang S, Arpornwirat W, Cheirsilpa A, et al. Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect Prev 2003;27:182-6
125. Numa F, Umayahara K, Suehiro Y, et al. Serum anti-p53 antibodies in uterine and ovarian cancer: association with DNA sequence copy number abnormalities. Tumor Biol 2001;22:162-8
126. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-5
127. Qiu T, Yang Q, Li XR, et al. Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters. Cancer Invest 2007;25:563-8
128. Lustgarten J, Domnguez AL, Pinilla C. Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope. J Immunol 2006;176:1796-805
129. Disis ML, Pupa SM, Gralow JR, et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-7
130. Kotlan B, Simsa P, Teillaud J-L, et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol 2005;175:2278-85
131. Nakamura O, Iwamori M, Matsutani M, Takakura K. Ganglioside GD3 shedding by human gliomas. Acta Neurochir 1991;109:34-6
132. Lewartowska A, Pacuszka T, Adler G, et al. Ganglioside reactive antibodies of IgG and IgM class in sera of patients with differentiated thyroid cancer. Immunol Lett 2002;80:129-32
133. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120-6
134. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35
135. Zhang JY, Casiano CA, Peng XX, et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003;12:136-43
136. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003;21:57-63
137. Scofield RH. Autoantibodies as predictors of disease. Lancet 2004;363:1544-6
138. Kowal C, DeGiorgio LA, Naltaoka T, et al. Cognition and immunity: antibody impairs memory. Immunity 2004;21:179-88
139. Peterson LK, Tsunoda I, Masaki T, Fujinami RS. Polyreactive myelin oligodendrocyte glycoprotein antibodies: implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis. J Neuroimmunol 2007;183:69-80
140. Pachner AR, Brady J, Narayan K. Antibody-secreting cells in the central nervous system in an animal model of MS: phenotype, association with disability, and in vitro production of antibody. J Neuroimmunol 2007;190:112-20
141. Ponomarenko NA, Durova OM, Vorobiev II, et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci USA 2006;103:281-6
142. Garg N, Zivadinov R, Ramanathan M, et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 2007;187:159-65
143. + T lymphocytes. Science 2008;319:215-20
144. Vojdani A, Campbell A, Anyanwu E, et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus Group A. J Neuroimmunol 2002;129:168-77
145. Vojdani A, O'Bryan T, Green JA, et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neurosci 2004;7(3):151-61
146. Vojdani A, Cooper EL. Antibodies against central nervous system antigens in autism: possible cross-reaction with dietary proteins and infectious agent antigens. In: Fatemi SH, editor, Neuropsychiatric disorders and infection. Taylor & Francis Ltd, London; 2005. p. 171-86
147. Vojdani A, Thrasher JD. Cellular and humoral immune abnormalities in Gulf War veterans. Environ Health Perspect 2004;112(8):840-6
148. Quintana FJ, Hagedorn PH, Elizur G, et al. Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc Natl Acad Sci USA 2004;101(Suppl 2):14615-21
149. Kenir H, Kreymborg K, Ifergan I, et al. Human Th17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173-5
150. Stromnes IM, Cerreti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by Th1 and Th17 cells. Nat Med 2008;14:337-42
151. Milward EA, Fitzsimmons C, Szklarczyk A, Conant K. The matrix metalloproteinases and CNS plasticity: an overview. J Neuroimmunol 2007;187:9-19
152. Aktas O, Waiczies S, Zipp F. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. J Neuroimmunol 2007;184:17-26
153. Schmidt LD, Xie Y, Lyte M, et al. Autonomic neurotransmitters modulate immunoglobulin A secretion in porcine colonic mucosa. J Neuroimmunol 2007;185:20-8
154. Alvarez JI, Teale JM. Differential changes in junctional complex proteins suggest the ependymal lining as the main source of leukocyte infiltration into ventricles in routine neurocysticercosis. J Neuroimmunol 2007;187:102-13
155. Watts T, Berti I, Sapone A, et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci USA 2005;102:2916-21
156. Domenici E, Muglia P. The search for peripheral disease markers in psychiatry by genomic and proteomic approaches. Expert Opin Med Diagn 2007;1(2):235-51